Ratings SyntheticMR AB

Equities

SYNT

SE0015987946

End-of-day quote NORDIC GROWTH MARKET Other stock markets 06:00:00 2024-01-30 pm EST			5-day change	1st Jan Change
27.7 ^SEK	+1.09%		-.--%	+4.14%

Apr. 17	SyntheticMR AB and SimonMed Imaging Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from Synthetic Software at SimonMed Facilities	CI
Mar. 27	SyntheticMR Receives FDA 510(k) Clearance for Their Next Generation Solution SyMRI 3D	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
According to Refinitiv, the company's ESG score for its industry is poor.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.

Weaknesses

With an expected P/E ratio at 50.36 and 28.85 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Based on current prices, the company has particularly high valuation levels.
The valuation of the company is particularly high given the cash flows generated by its activity.
The company is not the most generous with respect to shareholders' compensation.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
SYNTHETICMR AB	+4.14%	108M		D
VEEVA SYSTEMS INC.	+9.32%	33.88B		C
PRO MEDICUS LIMITED	+21.99%	8.35B		C-
SECTRA AB	+31.37%	4.24B		B-
EVOLENT HEALTH, INC.	-29.99%	2.67B		C-
OMNICELL, INC.	-18.80%	1.45B		B
VERADIGM INC.	-25.64%	1.33B	-	C+
LUNIT INC.	-33.21%	1.16B		-
SIMULATIONS PLUS, INC.	+13.31%	1B		C
B-SOFT CO.,LTD.	-34.50%	892M		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders